Relapsing MS: Greater Treatment Satisfaction Following Switch to Teriflunomide

Share this content:
Investigators reviewed patient-reported outcomes to assess treatment satisfaction with teriflunomide and also looked at feedback from physicians.
Investigators reviewed patient-reported outcomes to assess treatment satisfaction with teriflunomide and also looked at feedback from physicians.

According to study results published in Multiple Sclerosis and Related Disorders, patients with relapsing multiple sclerosis (MS) reported greater treatment satisfaction after they switched to teriflunomide from other disease-modifying therapies (DMTs).

A total of 1000 patients with relapsing forms of MS from 14 countries were enrolled in the phase 4, open-label study. During a 48-week study period, patients from all study sites, except in the United States, received once-daily 14 mg teriflunomide. Patients in the United States received either 7 mg or 14 mg, as deemed best by the treating neurologist. Of the entire cohort, a total of 594 switched from other DMTs to the study drug within 6 months before study start.

Global satisfaction with teriflunomide, as assessed by the Treatment Satisfaction Questionnaire for Medication, comprised the primary endpoint. Additional outcomes assessed included the changes from baseline to the 48-week study endpoint on the Patient-Determined Disease Steps, Multiple Sclerosis Performance Scale, Multiple Sclerosis International Quality of Life, and Stern Leisure Activity Scale.

Mean physician-reported cognitive outcome measures remained stable in patients who switched from another DMT to teriflunomide from baseline (0.975; 95% CI, 0.971-0.979) to week 48 (0.978; 95% CI, 0.974-0.982) (P =.8074). Patient-reported measures for treatment satisfaction, however, significantly improved from baseline to 48-week follow-up (46 vs 65.1, respectively; P <.0001). In addition, patients also reported significant improvements from baseline to week 48 in convenience (57.4 vs 72.4, respectively; P <.0001), intolerance (50.9 vs 71.1, respectively; P <.0001), and adverse effects (49.7 vs 67.2, respectively; P <.0001). Slight improvements from baseline to week 48 were also reported in assessments that evaluated disability worsening (3.1 vs 3), cognition (0.975 vs 0.978), and quality of life (67.5 vs 69.5).

Limitations of the study included the reliance on self-reports for evaluating treatment outcomes, its single-arm design, and its observational nature.

The findings from this study "demonstrate the global value of teriflunomide to patients in a real-world clinical practice setting and show consistent outcomes in the subset of patients switching to teriflunomide," the researchers wrote.

Reference

Coyle PK, Khatri B, Edwards KR, et al; for the Teri-PRO Trial Group. Patient-reported outcomes in patients with relapsing forms of MS switching to teriflunomide from other disease-modifying therapies: Results from the global Phase 4 Teri-PRO study in routine clinical practice. Mult Scler Relat Disord. 2018;26:211–218.

You must be a registered member of Neurology Advisor to post a comment.

Sign Up for Free e-newsletters



CME Focus